友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02496 友芝友生物-B

停牌 09-03 11:10:19

3.300

+0.000

0.00%

最高3.300	最低3.300	成交量0.00
今开3.300	昨收3.300	日振幅0.00%
总市值6.40亿	流通市值5.92亿	总股本1.94亿
成交额0.00	换手率0.00%	流通股本1.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02496","market":"HK","secType":"STK","nameCN":"友芝友生物-B","latestPrice":3.3,"timestamp":1788398419927,"preClose":3.3,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":179479113,"shares":194000000,"eps":-0.5102345907679279,"marketStatus":"停牌","change":0,"latestTime":"09-03 11:10:19","open":3.3,"high":3.3,"low":3.3,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.18757383535667235,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1788408000000},"marketStatusCode":2,"adr":0,"listingDate":1695571200000,"exchange":"SEHK","adjPreClose":3.3,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02496","defaultTab":"news","newsList":[{"id":"2663234790","title":"友芝友生物-B于8月31日起短暂停牌 待刊发内幕消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2663234790","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663234790?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:05","pubTimestamp":1788138300,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端友芝友生物-B（02496）发布公告，公司股份已自2026年8月31日上午九时正起暂停于香港联合交易所有限公司买卖，以待根据公司收购、合并及股份回购守则刊发载有公司内幕消息的公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-31/doc-iniqehxc9216031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663236270","title":"友芝友生物-B(02496.HK)8月31日起短暂停牌 待刊发内幕消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2663236270","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663236270?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:56","pubTimestamp":1788137784,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142371189","title":"友芝友生物-B（02496）8月31日起停牌 待发布涉及公司收购合并及股份回购守则的内幕消息","url":"https://stock-news.laohu8.com/highlight/detail?id=1142371189","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142371189?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:56","pubTimestamp":1788137770,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司8月31日在港交所发布公告称，应公司要求，其股份自2026年8月31日上午九时正起暂停买卖。停牌原因系公司将根据《公司收购、合并及股份回购守则》刊发载有内幕消息的公告。公司提醒投资者，港交所及香港结算所有限公司对本公告内容的准确性或完整性不承担任何责任，并明确表示概不因本公告全部或任何部分内容而承担任何损失责任。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663023622","title":"友芝友生物-B(02496.HK)8月31日起短暂停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2663023622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663023622?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:55","pubTimestamp":1788137734,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662806315","title":"友芝友生物-B(02496)发布中期业绩 净亏损626万元 同比收窄89.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662806315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662806315?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:15","pubTimestamp":1787908537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布截至2026年6月30日止6个月中期业绩，集团收入人民币3314.3万元，同比减少10.87%;净亏损626万元，同比收窄89.36%;研发开支1758.1万元，同比减少70.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131513878","title":"友芝友生物-B2026年中期财报：营收3,314.30万元，净亏损626.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131513878","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131513878?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:54","pubTimestamp":1787907298,"startTime":"0","endTime":"0","summary":"2026年上半年，公司营收3,314.30万元，同比下降10.88%。同期净亏损626.00万元，上年同期亏损5,883.40万元，亏损同比收窄约89.36%。本期毛利2,525.60万元，毛利率达76.2%，而上年同期毛利率约为20.62%。经营活动现金流量由上年同期净流入1,220.00万元转为本期净流出2,660.00万元。从成本结构看，报告期内公司研发开支1,758.10万元，占总营收约53%。报告期内主要收入来源包括许可费收入和研发服务收入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"友芝友生物-B2026年中期财报：营收3,314.30万元，净亏损626.00万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127507772","title":"友芝友生物-B将于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1127507772","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127507772?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:46","pubTimestamp":1787042809,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司（股票代码：02496，股票简称：友芝友生物-B）公告称，董事会已排定于2026年8月28日（星期五）召开会议。董事会将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩报告，并讨论相关发布事宜及其他事项。董事会由董事长、执行董事兼首席执行官Zhou Pengfei博士召集。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658226229","title":"友芝友生物-B创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2658226229","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658226229?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:31","pubTimestamp":1786519862,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186473636","title":"友芝友生物-B7月股份变动月报，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1186473636","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186473636?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:44","pubTimestamp":1785919496,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司于2026年8月5日发布2026年7月股份变动月报。报告期覆盖2026年7月，公告显示公司股本结构及发行股份数量在本月内均无显著变动。其中，H股股本维持在179,479,113股，内资股股本维持在14,370,087股，月度内均未发生增减变化。公司表示期内未进行任何股份增发或回购注销事宜，H股和内资股股本数量保持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125309281","title":"友芝友生物-B6月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125309281","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125309281?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:52","pubTimestamp":1783327960,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司于2026年7月6日发布2026年6月股份变动月报表。报告期内，公司注册股本总额保持在人民币193,849,200元，其中H股179,479,113股与内资股14,370,087股维持不变，合计已发行股份数量无新增或回购注销情况。公司确认其公众持股量符合香港联交所相关上市规定。公司强调，其持续严格遵守香港联交所《上市规则》及相关法律法规各项规定。本次公告由联席公司秘书郑建华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163663396","title":"友芝友生物-B 2026年5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1163663396","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163663396?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:36","pubTimestamp":1780475794,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司于2026年6月3日披露2026年5月股份变动月报，报告期为截至2026年5月31日。根据公告披露数据，截至当月末，公司股本基本维持稳定，未发生新增发行、回购或注销股份的情况。报告显示，截至2026年5月31日，公司的法定/注册股本总额为193,849,200元人民币，其中H股179,479,113股，面值每股1元，内资股14,370,087股，面值每股1元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637311357","title":"友芝友生物-B(02496)：M701“CD3/EpCAM双特异性抗体”两项临床研究数据将于2026ASCO年会进行展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2637311357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637311357?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:05","pubTimestamp":1779451520,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布公告，公司核心国家1类创新药M701“CD3/EpCAM双特异性抗体”的两项临床研究结果将于2026年美国临床肿瘤学会(ASCO)年会上进行展示：针对恶性腹水(MA)的III期注册临床研究、针对非小细胞肺癌(NSCLC)相关恶性胸水(MPE)的II期临床研究。M701的上市申请已于2026年5月获中国国家药品监督管理局药品审评中心(CDE) 受理，有望成为中国首个恶性胸腹水标准治疗方案。相比欧盟获批的卡妥索单抗，M701展现出更优的安全性与切实的临床可及性;相比穿刺引流或局部化疗，M701则体现出更高的有效率和更持久的积液控制能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635704166","title":"友芝友生物-B(02496)：方丽娟获选举为第二届监事会职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2635704166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635704166?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:35","pubTimestamp":1778834112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布公告，石剑博士(石博士)因个人职业发展原因而辞去本公司职工代表监事职务，自2026年5月15日起生效。本公司抗体平台部副总监方丽娟女士(方女士)于2026年5月15日获职工代表大会民主选举为第二届监事会职工代表监事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161026826","title":"友芝友生物-B更新4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1161026826","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161026826?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:53","pubTimestamp":1778057634,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司于2026年5月6日发布截至2026年4月30日止的股份变动月报表。根据公告，报告期内公司已发行股份及注册股本均无变化，股本维持稳定。报告期末，H股已发行股份数为179,479,113股，内资股已发行股份数为14,370,087股，合计已发行股份总数保持在193,849,200股，未发生新增发行、回购或注销等变动。在购股权计划方面，公司于2024年6月27日通过了2024年H股购股权计划，报告期内无因期权行使而产生的新股发行，亦无库存股份变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009835","title":"友芝友生物-B(02496)：M 701两项研究成果获选于2026 ASCO年会进行展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009835","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629009835?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:36","pubTimestamp":1776944163,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布公告，本公司核心创新双特异性抗体产品(M 701)两项临床研究成果成功入选2026年美国临床肿瘤学会(ASCO)年会。其中，M 701用于恶性腹水的III期临床研究成果入选大会临床科学研讨会口头报告;同时，M 701用于恶性胸腔积液的II期临床研究成果入选大会海报展示。这是M 701项目在国际肿瘤学术舞台上的又一重要里程碑，体现了M 701在恶性浆膜腔积液治疗领域持续获得国际学术界关注与认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133540584","title":"友芝友生物-B(02496)2025年业绩：收入6685.8万元 研发投入回落 亏损同比收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1133540584","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133540584?lang=zh_cn&edition=full","pubTime":"2026-04-16 23:15","pubTimestamp":1776352515,"startTime":"0","endTime":"0","summary":"2025年度，友芝友生物-B收入为人民币6685.8万元，较2024年的1.0781亿元下降约38.0%。毛利为1073.5万元，同比下滑87.4%，主要因收入规模收缩及成本增加所致。年内除税前亏损约8473.2万元，相比2024年收窄13.2%，研发支出则由1.6499亿元降至7819.8万元，显示公司在控制费用方面取得一定成效。同时，公司现金及现金等价物在年末降至1.00065亿元，流动资产与流动负债对比呈现一定压力，资产净值由2024年底的正值转为负数。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132405667","title":"友芝友生物-B3月股份变动月报表，完成68,010,299股非上市股份转换为H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1132405667","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132405667?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:36","pubTimestamp":1775640970,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司于2026年4月8日发布截至2026年3月31日的股份变动月报表。月报显示，公司于报告期内完成非上市股份转换为H股的相关工作，股本结构随之发生明显变动。根据公告，报告期内H股数量由此前的111,468,814股增至179,479,113股，增加部分为68,010,299股；与此同时，内资股数量从75,510,642股降至14,370,087股，非上市外资股则由6,869,744股降至0。公司在完成上述转换后，截至3月底的法定注册资本合计为193,849,200股，标志着H股全流通顺利完成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390729","title":"友芝友生物-B(02496)：完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390729","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623390729?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:57","pubTimestamp":1774861075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布公告，于2026年3月30日完成将合共6801.03万股非上市股份转换为H股，而转换后H股将于2026年3月31日上午九时正于联交所开始上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156483037","title":"友芝友生物-B完成已发行股本变动，H股增至1.79亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1156483037","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156483037?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:57","pubTimestamp":1774861024,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司（股票名称：友芝友生物-B，股票代码：02496）于2026年3月30日发布翌日披露报表，公告其已发行股本发生变动。根据公告，公司将61,140,555股内资股和6,869,744股非上市外资股转换为共计68,010,299股H股。\n此次股本变动占本次变动前公司已发行股份（不含库藏股）约61.01%，完成后公司H股由111,468,814股增加至179,479,113股，内资股和非上市外资股则相应减少。公司在公告中确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规，相关董事会授权程序已完成。\n公告由联席公司秘书郑建华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622822490","title":"友芝友生物-B(02496)发布年度业绩 年内亏损8473.2万元 同比收窄13.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622822490","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622822490?lang=zh_cn&edition=full","pubTime":"2026-03-27 21:29","pubTimestamp":1774618178,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布截至2025年12月31日止年度业绩，该集团取得收入6685.8万元(人民币，下同)，同比减少37.99%;年内亏损8473.2万元，同比收窄13.18%;每股基本亏损0.44元。公告称，集团于报告期的亏损减少主要是由于收入减少人民币4100万元;于报告期内的收入成本较同期增加人民币3340万元;及于报告期内的研发开支较同期减少人民币8680万元。上述各项抵销，使得报告期的亏损及综合开支总额较同期有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.yzybio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1033},{"period":"3month","weight":-0.2143},{"period":"6month","weight":-0.5147},{"period":"1year","weight":-0.4},{"period":"ytd","weight":-0.5885}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"武汉友芝友生物制药股份有限公司是一家主要从事发现、开发及商业化抗肿瘤双特异性抗体方面的新型创新药物的中国公司。该公司致力于开发用于治疗癌症相关并发症、癌症及老年性眼科疾病的基于双特异性抗体（BsAb）疗法，以解决肿瘤学及老年眼科病领域的医疗需求。该公司的核心产品M701是一种靶向人癌细胞表面抗原EpCAM和人T细胞表面抗原CD3的重组BsAb。该公司的产品管线还包括Y101D、Y332、Y225等。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.118093},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131504},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.057977},{"month":5,"riseRate":0,"avgChangeRate":-0.055072},{"month":6,"riseRate":0.666667,"avgChangeRate":0.03104},{"month":7,"riseRate":0.333333,"avgChangeRate":0.022644},{"month":8,"riseRate":0,"avgChangeRate":-0.093838},{"month":9,"riseRate":0.666667,"avgChangeRate":0.112704},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141485},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.141267},{"month":12,"riseRate":1,"avgChangeRate":0.323325}],"exchange":"SEHK","name":"友芝友生物-B","nameEN":"YZYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"友芝友生物-B,02496,友芝友生物-B股票,友芝友生物-B股票老虎,友芝友生物-B股票老虎国际,友芝友生物-B行情,友芝友生物-B股票行情,友芝友生物-B股价,友芝友生物-B股市,友芝友生物-B股票价格,友芝友生物-B股票交易,友芝友生物-B股票购买,友芝友生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}